Natural Health Farm (NHEL) 10-Q 17 Aug 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information	9 Months Ended
	Jun. 30, 2017shares
Document And Entity Information
Entity Registrant Name	NATURAL HEALTH FARM HOLDINGS INC
Entity Central Index Key	1,621,697
Document Type	10-Q
Trading Symbol	NHEL
Document Period End Date	Jun. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding	150,150,000
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,017

Condensed Balance Sheets (unaud

Condensed Balance Sheets (unaudited) - USD ($)	Jun. 30, 2017	Sep. 30, 2016
Current Assets
Prepaid Expenses		$ 696
Total Current Assets		696
Total Assets		696
Current Liabilities
Other payables	2,070
Amount due to shareholders	23,643
Loan from director	4,982	5,703
Total Liabilities	30,695	5,703
Stockholders' Equity
Common stock, par value $ 0.000033; 500,000,000 shares authorized, 150,150,000 shares issued and outstanding;	5,005	5,005
Additional paid in capital	28,342	19,095
Deficit accumulated during the development stage	(64,042)	(29,107)
Total Stockholders' Equity (Deficit)	$ (30,695)	(5,007)
Total Liabilities and Stockholders' Equity		$ 696

Condensed Balance Sheets (unau3

Condensed Balance Sheets (unaudited) (Parenthetical) - $ / shares	Jun. 30, 2017	Sep. 30, 2016
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.000033	$ 0.000033
Common stock, authorized	500,000,000	500,000,000
Common stock, issued	150,150,000	150,150,000
Common stock, outstanding	150,150,000	150,150,000

Condensed Statements of Operati

Condensed Statements of Operations (unaudited) - USD ($)	6 Months Ended		9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Statement [Abstract]
REVENUES		$ 1,000		$ 1,000
OPERATING EXPENSES
Professional Fees	25,790	10,169	34,935	18,596
Bank Service Charges		469		1,245
General and Administrative Expenses		40		40
TOTAL OPERATING EXPENSES	25,790	10,678	34,935	19,881
NET LOSS FROM OPERATIONS	(25,790)	(9,678)	(34,935)	(18,881)
PROVISION FOR INCOME TAXES
NET LOSS	$ (25,790)	$ (9,678)	$ (34,935)	$ (18,881)
NET LOSS PER SHARE: BASIC AND DILUTED (in dollars per share)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED (in shares)	150,150,000	5,005,000	150,150,000	4,828,633

Condensed Statement of Cash Flo

Condensed Statement of Cash Flows (unaudited) - USD ($)	6 Months Ended		9 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Sep. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss for the period	$ (25,790)	$ (9,678)	$ (34,935)	$ (18,881)
Changes in assets and liabilities:
Decrease in prepaid expenses			696
Increase in accrual and other payables			2,070	692
CASH FLOWS USED IN OPERATING ACTIVITIES			(32,169)	(18,189)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of common stock				1,005
Increase in loan from existing director			8,526
Increase in amount due to shareholders			23,643
Increase in additional paid in capital			9,247	19,095
Forgiveness of debt from former director			(9,247)
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES			32,169	20,100
NET INCREASE IN CASH				1,911
Cash, beginning of period				427	$ 427
Cash, end of period		$ 2,338		2,338
SUPPLEMENTAL CASH FLOW INFORMATION:
Interest paid
Income taxes paid

Condensed Statement of Cash Fl6

Condensed Statement of Cash Flows (unaudited) (Parenthetical)	9 Months Ended
	Jun. 30, 2017USD ($)
Non-cash transaction:
Forgiveness of debt from former director	$ 9,247

ORGANIZATION AND NATURE OF BUSI

ORGANIZATION AND NATURE OF BUSINESS	9 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND NATURE OF BUSINESS	NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS Natural Health Farm Holdings Inc. (formerly known as Amber Group Inc.) was incorporated under the laws of the State of Nevada on July 10, 2014. Our address is 1980 Festival Plaza Drive Suite 530 Las Vegas, Nevada 89135. On November 29, 2016, Mr. Tee Chuen Meng was appointed as President and Chief Executive Officer, Secretary and Treasurer of our company. On November 29, 2016, Vadims Furss resigned as President, Chief Executive Officer, Secretary and Treasurer of our company. On November 30, 2016, we filed a certificate of amendment to our articles of incorporation with the Nevada Secretary of State to change our name to “Natural Health Farm Holdings Inc.” and affect a 30:1 forward stock split of our common stock and increase our Authorized Share Capital to 500,000,000 (Five Hundred Million). This amendment was unanimously approved by our board of directors on November 29, 2016, Stockholders holding a majority of our voting power took action by written consent approving an amendment to our articles of incorporation to change the name of the company to a name to be determined by the board of directors and 30:1 forward stock split and increase our Authorized to 500,000,000 in its sole discretion, and authorized the Board of Directors to file the Amendment upon a determination and resolution of the Board of Directors of such new corporate name and 30;1 forward stock split. On March 16, 2017. FINRA has approved the corporate name change to “Natural Health Farm Holdings Inc,” an increase in our authorized shares of common stock to 500,000,000 shares and a 30:1 forward stock split effective March 17, 2017. The new trading symbol for our common stock is “NHEL”.

SUMMARY OF SIGNIFCANT ACCOUNTIN

SUMMARY OF SIGNIFCANT ACCOUNTING POLICIES	9 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
SUMMARY OF SIGNIFCANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFCANT ACCOUNTING POLICIES Development Stage Company The Company is a development stage company as defined by section 915-10-20 of the FASB Accounting Standards Codification. The Company is devoting substantially all of its efforts on establishing the business and its planned principal operations have not commenced. All losses accumulated since inception have been considered as part of the Company's development stage activities. The Company has elected to adopt early application of Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. Upon adoption, the Company no longer presents or discloses inception-to-date information and other remaining disclosure requirements of Topic 915. Interim Financial Statements The interim financial statements are condensed and should be read in conjunction with the company's latest annual financial statements and it is management's opinion that all adjustments necessary for a fair presentation for the interim periods have been made, and that all adjustments are of a normal recurring nature that there were no adjustments other than normal recurring adjustments. The results for the three months ended June 30, 2017 are not necessarily indicative of the results of operations for the full year. These financial statements and related footnotes should be read in conjunction with the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10K for the year ended September 30, 2016, filed with the Securities and Exchange Commission. The accompanying condensed financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at June 30, 2017 and for the related periods presented. Basis of Presentation The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars. Going Concern The accompanying financial statements have been prepared in conformity with generally accepted accounting principle, which contemplate continuation of the Company as a going concern. However, the Company had no revenues as of June 30, 2017. The Company currently has limited working capital, and has not completed its efforts to establish a stabilized source of revenues sufficient to cover operating costs over an extended period of time. Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses The Company intends to position itself so that it may be able to raise additional funds through the capital markets. In light of management’s efforts, there are no assurances that the Company will be successful in this or any of its endeavors or become financially viable and continue as a going concern. Accounting Basis The Company uses the accrual basis of accounting and accounting principles generally accepted in the United States of America (“GAAP” accounting). The Company has adopted a September 30 fiscal year end. Fair Value of Financial Instruments The Company’s financial instruments consist of amounts due to shareholder. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. Income Taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. Revenue Recognition The Company recognizes revenue when products are fully delivered or services have been provided and collection is reasonably assured. The Company had no revenues as of June 30, 2017. Stock-Based Compensation Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. To date, the Company has not adopted a stock option plan and has not granted any stock options. Basic Income (Loss) Per Share Basic income (loss) per share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Company’s net income available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There are no such common stock equivalents outstanding as of June 30, 2017. Comprehensive Income The Company has which established standards for reporting and display of comprehensive income, its components and accumulated balances. When applicable, the Company would disclose this information on its Statement of Stockholders’ Equity. Comprehensive income comprises equity except those resulting from investments by owners and distributions to owners. The Company has not had any significant transactions that are required to be reported in other comprehensive income. Recent Accounting Pronouncements In September 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-10, “Development Stage Entities”. The amendments in this update remove the definition of a development stage entity from the Master Glossary of the ASC thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments in this update are applied retrospectively. The adoption of ASU 2014-10 removed the development stage entity financial reporting requirements for the Company.

LOANS FROM DIRECTOR AND SHAREHO

LOANS FROM DIRECTOR AND SHAREHOLDERS	9 Months Ended
	Jun. 30, 2017
Related Party Transactions [Abstract]
LOANS FROM DIRECTOR AND SHAREHOLDERS	NOTE 3 – LOANS FROM DIRECTOR AND SHAREHOLDERS The loan from the former director as of September 30, 2016 was $5,703. $3,544 was subsequently loaned and the entire balance of the former shareholder of $9,247 was forgiven as of December 31, 2016. As of June 30, 2017, a director and shareholders loaned $4,982 and $23,643 respectively for Company’s business expenses. The loans are unsecured, non-interest bearing and due on demand.

COMMON STOCK

COMMON STOCK	9 Months Ended
	Jun. 30, 2017
Equity [Abstract]
COMMON STOCK	NOTE 4 – COMMON STOCK On September 29, 2014, the Company issued 120,000,000 shares of common stock for cash proceeds of $4,000 at $0.000033 per share. As of December 31, 2015, the Company issued 20,475,000 shares of common stock for cash proceeds of $13,650 at $0.00066 per share. As of June 30, 2016, the Company issued 9,675,000 shares of common stock for cash proceeds of 6,450 at $0.00066 per share. On November 30, 2016, the Company affect a 30:1 forward stock split of the common stock and increase the Authorized Share Capital to from 75,000,000 to 500,000,000. There were 150,150,000 shares of common stock issued and outstanding as of June 30, 2017.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 5 – COMMITMENTS AND CONTINGENCIES The Company neither owns nor leases any real or personal property. An officer has provided office services without charge. There is no obligation for the officer to continue this arrangement. Such costs are immaterial to the financial statements and accordingly are not reflected herein. The officers and directors are involved in other business activities and most likely will become involved in other business activities in the future.

PREPAID EXPENSES

PREPAID EXPENSES	9 Months Ended
	Jun. 30, 2017
Prepaid Expenses Details Narrative
PREPAID EXPENSES	NOTE 6 - PREPAID EXPENSES As of June 30 2017, the Company has no prepaid expenses. The Company has prepaid their expenses to the auditor in the amount of $696 as of September 30, 2016.

OTHER PAYABLES

OTHER PAYABLES	9 Months Ended
	Jun. 30, 2017
Other Liabilities Disclosure [Abstract]
OTHER PAYABLES	NOTE 7 – OTHER PAYABLES As of June 30, 2017 the Company has professional fee payable to the lawyer in amount of $2,070.

INCOME TAXES

INCOME TAXES	9 Months Ended
	Jun. 30, 2017
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 8 – INCOME TAXES As of June 30, 2017, the Company had net operating loss carry forwards of approximately $64,042 that may be available to reduce future years’ taxable income in varying amounts through 2031. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as their realization is determined not likely to occur and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards. The provision for Federal income tax consists of the following: September 30, June 30, 2017 Federal income tax benefit attributable to: Current Operations $ 6,867 $ 11,878 Less: valuation allowance (6,867 ) (11,878 ) Net provision for Federal income taxes $ - $ - The cumulative tax effect at the expected rate of 34% of significant items comprising our net deferred tax amount is as follows: September 30, June 30, 2017 Deferred tax asset attributable to: Net operating loss carryover $ 9,896 $ 21,774 Less: valuation allowance (9,896 ) (21,774 ) Net deferred tax asset $ - $ - Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards of approximately $64,042 for Federal income tax reporting purposes are subject to annual limitations. Should a change in ownership occur net operating loss carry forwards may be limited as to use in future years.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Jun. 30, 2017
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 9 – SUBSEQUENT EVENTS In accordance with SFAS 165 (ASC 855-10) the Company has analyzed its operations subsequent to June 30, 2017 to the date these financial statements were issued on 8 August 2017, and has determined that it does not have any material subsequent events to disclose in these financial statements.

SUMMARY OF SIGNIFCANT ACCOUNT16

SUMMARY OF SIGNIFCANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Development Stage Company	Development Stage Company The Company is a development stage company as defined by section 915-10-20 of the FASB Accounting Standards Codification. The Company is devoting substantially all of its efforts on establishing the business and its planned principal operations have not commenced. All losses accumulated since inception have been considered as part of the Company's development stage activities. The Company has elected to adopt early application of Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. Upon adoption, the Company no longer presents or discloses inception-to-date information and other remaining disclosure requirements of Topic 915.
Interim Financial Statements	Interim Financial Statements The interim financial statements are condensed and should be read in conjunction with the company's latest annual financial statements and it is management's opinion that all adjustments necessary for a fair presentation for the interim periods have been made, and that all adjustments are of a normal recurring nature that there were no adjustments other than normal recurring adjustments. The results for the three months ended June 30, 2017 are not necessarily indicative of the results of operations for the full year. These financial statements and related footnotes should be read in conjunction with the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10K for the year ended September 30, 2016, filed with the Securities and Exchange Commission. The accompanying condensed financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at June 30, 2017 and for the related periods presented.
Basis of Presentation	Basis of Presentation The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars.
Going Concern	Going Concern The accompanying financial statements have been prepared in conformity with generally accepted accounting principle, which contemplate continuation of the Company as a going concern. However, the Company had no revenues as of June 30, 2017. The Company currently has limited working capital, and has not completed its efforts to establish a stabilized source of revenues sufficient to cover operating costs over an extended period of time. Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses The Company intends to position itself so that it may be able to raise additional funds through the capital markets. In light of management’s efforts, there are no assurances that the Company will be successful in this or any of its endeavors or become financially viable and continue as a going concern.
Accounting Basis	Accounting Basis The Company uses the accrual basis of accounting and accounting principles generally accepted in the United States of America (“GAAP” accounting). The Company has adopted a September 30 fiscal year end.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s financial instruments consist of amounts due to shareholder. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements.
Income Taxes	Income Taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Revenue Recognition	Revenue Recognition The Company recognizes revenue when products are fully delivered or services have been provided and collection is reasonably assured. The Company had no revenues as of June 30, 2017.
Stock-Based Compensation	Stock-Based Compensation Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. To date, the Company has not adopted a stock option plan and has not granted any stock options.
Basic Income (Loss) Per Share	Basic Income (Loss) Per Share Basic income (loss) per share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Company’s net income available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There are no such common stock equivalents outstanding as of June 30, 2017.
Comprehensive Income	Comprehensive Income The Company has which established standards for reporting and display of comprehensive income, its components and accumulated balances. When applicable, the Company would disclose this information on its Statement of Stockholders’ Equity. Comprehensive income comprises equity except those resulting from investments by owners and distributions to owners. The Company has not had any significant transactions that are required to be reported in other comprehensive income.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In September 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-10, “Development Stage Entities”. The amendments in this update remove the definition of a development stage entity from the Master Glossary of the ASC thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments in this update are applied retrospectively. The adoption of ASU 2014-10 removed the development stage entity financial reporting requirements for the Company.

INCOME TAXES (Tables)

INCOME TAXES (Tables)	9 Months Ended
	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Schedule of provision for federal income tax	The provision for Federal income tax consists of the following: September 30, June 30, 2017 Federal income tax benefit attributable to: Current Operations $ 6,867 $ 11,878 Less: valuation allowance (6,867 ) (11,878 ) Net provision for Federal income taxes $ - $ -
Schedule of deferred tax amount	The cumulative tax effect at the expected rate of 34% of significant items comprising our net deferred tax amount is as follows: September 30, June 30, 2017 Deferred tax asset attributable to: Net operating loss carryover $ 9,896 $ 21,774 Less: valuation allowance (9,896 ) (21,774 ) Net deferred tax asset $ - $ -

ORGANIZATION AND NATURE OF BU18

ORGANIZATION AND NATURE OF BUSINESS (Details Narrative) - shares	Nov. 30, 2016	Jun. 30, 2017	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Revised common stock, authorized	500,000,000	500,000,000	500,000,000
Description of forward stock split	30:1 forward stock split

LOANS FROM DIRECTOR AND SHARE19

LOANS FROM DIRECTOR AND SHAREHOLDERS (Details Narrative) - USD ($)	9 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Sep. 30, 2016	Mar. 31, 2017
Defined Benefit Plan Disclosure [Line Items]
Loan from the director	$ 4,982		$ 5,703
Loan from the shareholder	23,643
Additional loan from the former director	$ 8,526
Forgiveness of debt from former shareholder				$ 9,247
Former Director [Member] | Loans Payable [Member]
Defined Benefit Plan Disclosure [Line Items]
Additional loan from the former director			$ 3,544

COMMON STOCK (Details Narrative

COMMON STOCK (Details Narrative) - USD ($)	Nov. 30, 2016	Jun. 30, 2016	Dec. 31, 2015	Sep. 29, 2014	Jun. 30, 2017	Sep. 30, 2016
Equity [Abstract]
Number of shares issued upon cash		9,675,000	20,475,000	120,000,000
Value of shares issued upon cash		$ 6,450	$ 13,650	$ 4,000
Share price (in dollars per share)		$ 0.00066	$ 0.00066	$ 0.000033
Description of forward stock split	30:1 forward stock split
Previously common stock, authorized	75,000,000
Revised common stock, authorized	500,000,000				500,000,000	500,000,000
Common stock, issued					150,150,000	150,150,000
Common stock, outstanding					150,150,000	150,150,000

PREPAID EXPENSES (Details Narra

PREPAID EXPENSES (Details Narrative) - USD ($)	Jun. 30, 2017	Sep. 30, 2016
Prepaid Expenses Details Narrative
Prepaid expenses		$ 696

OTHER PAYABLES (Details Narrati

OTHER PAYABLES (Details Narrative)	Jun. 30, 2017USD ($)
Other Liabilities Disclosure [Abstract]
Professional fee payable to lawyer	$ 2,070

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	9 Months Ended	12 Months Ended
	Jun. 30, 2017	Sep. 30, 2016
Federal income tax benefit attributable to:
Current Operations	$ 11,878	$ 6,867
Less: valuation allowance	(11,878)	(6,867)
Net provision for Federal income taxes

INCOME TAXES (Details 1)

INCOME TAXES (Details 1) - USD ($)	Jun. 30, 2017	Sep. 30, 2016
Deferred tax asset attributable to:
Net operating loss carryover	$ 21,774	$ 9,896
Less: valuation allowance	(21,774)	(9,896)
Net deferred tax asset

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative)	9 Months Ended
	Jun. 30, 2017USD ($)
Income Tax Disclosure [Abstract]
Income tax rate	34.00%
Net operating loss carry forwards	$ 64,042